Egyptian rousette bat humoral immunity to H9 influenza hemagglutinin
Roffler, A. A.; Schmidt, A.; Glassey, E.; Murphy, C. L.; Sordilla, S. L.; Peng, C. L.; Maurer, D. P.; Altan, E.; Forbes, K. M.; Sironen, T.; Bajic, G.; Bonnettaz, B.
Show abstract
In mammals, antibodies are central to antiviral defense, but they can also impose selective pressure that drives viral evolution. The interplay between viral antigenic variation and host antibody diversification constitutes a molecular arms race that influences pathogenicity, transmission, and spillover risk. Bats are reservoirs for zoonotic viruses with pandemic potential yet they appear to tolerate infection without overt disease. Although distinctive features of bat innate immunity have been described, the role of adaptive immunity--particularly antibody-mediated responses--remains largely undefined. Moreover, how antibody evolutionary pressure operates in bats is unknown, in part because tools to interrogate bat B cell responses at the monoclonal level are limited. Here, we developed a yeast surface display library of bat antibodies derived from splenic RNA of wild-caught Egyptian rousette bats to interrogate humoral responses to the bat-derived H9 influenza hemagglutinin. We isolated monoclonal antibodies recognizing the hemagglutinin (HA) antigen and defined their gene usage, somatic hypermutation frequency, binding affinities, and breadth. We then used cryo-EM to structurally characterize three bat antibodies in complex with HA engaging distinct antigenic sites. Together, these data enable direct comparison with human anti-influenza antibodies highlighting similarities in humoral immunity across mammals and provides a tool to examine bat antibody responses to other potential zoonotic viruses.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site via a recurring motif in CDR H3 98%
- HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design 97%
- Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients 97%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.